SM
ENTA icon

Sabby Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Sabby Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-85,946
Closed -$3.12M – 246
2013
Q4 		$2.35M Buy
+85,946
New +$2.08M 0.15% 74

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's ENTA Position: Q1 2014 in Review

Sabby Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2014, closing a stake of 85,946 shares — an estimated $3.12M sold.

Sabby Management first reported a position in ENTA in Q4 2013 and held it in 1 quarter. The position peaked at $2.35M in Q4 2013. 81 funds tracked by Wall St. Rank hold ENTA as of Q1 2014.

  • Sabby Management reported no remaining Enanta Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Sabby Management sold 85,946 Enanta Pharmaceuticals shares in Q1 2014, an estimated $3.12M.
  • Sabby Management first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Sabby Management's Enanta Pharmaceuticals position peaked at $2.35M in Q4 2013.
  • 81 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2014.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.